Sorry, you need to enable JavaScript to visit this website.

USPTO Cancer Patents Analyzer

USPTO Cancer Patents Analyzer is a visualization tool to gain insights from cancer patents data based on USTPO’s curated data set consisting 269,353 patent documents.

The tool provides dashboard and charts for analysis. In summary, the dashboard describes cancer patents data to provide users with counts of total patents, patents funded by NIH grants and patents that were successfully developed into treatments. It also shows a break-down of patent count by patent categories (bar-chart) to show which areas of cancer research has high focus by researchers and funding organization. Furthermore, there is a pie-chart to show how many patents were used to develop cancer treatment from 1976 to 2016 and a time-line chart to show increase or decrease in patent counts over period of time. Following are few key insights that a user can gain from the dashboard and charts:

  • Total federal funding received from 1976 to 2016 is just 2.71%.
  • Drug and Chemistry, DNA/RNA Protein Sequence and Diagnostic/Surgical Devices has been the top 3 areas for cancer research. Drug and Chemistry patents has received maximum federal funding. All Radiation Measurement patents were federally funded.
  • Only 0.4% of patents from 1976 to 2016 has been successfully developed into treatments.
  • Maximum number of patents (19,505) were granted in year 2014.
  • A decline in number of patents granted is observed from 2014 to 2015 (no significant data available for 2016).

Please click here to download the user guide: download

When you click on any of the above links within the Tableau visualization you will be leaving the United States Patent and Trademark Office (USPTO) Open Data Portal. The USPTO does not necessarily endorse the views expressed or the facts presented on this site. Further, the USPTO does not endorse any commercial products that may be advertised or available on this site. You may wish to review the privacy notice on those sites since their information collection practices may differ from ours.

  0 Comments

Leave a comment

To ensure that everyone can participate in polite conversation, these comments will be moderated. For detailed information on how and what we moderate, view our comment policy.